β2 integrins are heterodimeric surface receptors composed of a variable α (CD11a-CD11d)
and a constant β (CD18) subunit and are specifically expressed by leukocytes. The α …

Tumor‐targeting monoclonal antibodies are available for a number of cancer cell types
(over) expressing the corresponding tumor antigens. Such antibodies can limit tumor …

Tumor extracellular matrix has been associated with drug resistance and immune
suppression. Here, proteomic and RNA profiling reveal increased collagen levels in lung …

Destruction of cancer cells by therapeutic antibodies occurs, at least in part, through
antibody-dependent cellular cytotoxicity (ADCC), and this can be mediated by various Fc …

Monoclonal antibodies are among the most promising therapeutic agents for treating cancer.
Therapeutic cancer antibodies bind to tumor cells, turning them into targets for immune …

Rituximab is an anti-CD20 chimeric mAb effective for the treatment of B-NHL. It can lyse
lymphoma cells in vitro through both C-and Ab-dependent cellular cytotoxicity. The …

In recent years, interest in anti-cancer therapeutic monoclonal antibodies (mAb) has been
renewed. Several of these reagents have been approved for therapy in a variety of cancer …

The tumor-killing mechanisms available to monoclonal antibodies (mAbs; eg, antagonism of
growth factor receptors, antibody-dependent cell-mediated cytotoxicity) limit efficacy …

Because tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) preferentially
induces apoptosis in tumor cells and plays a critical role in tumor surveillance, its receptor is …

The use of monoclonal antibodies (mAbs) has become a mainstream strategy for the
treatment of cancer. After binding to the target antigen, they mediate a plethora of effector …